Home > Journals > The Journal of Cardiovascular Surgery > Past Issues > The Journal of Cardiovascular Surgery 2015 February;56(1) > The Journal of Cardiovascular Surgery 2015 February;56(1):89-95





A Journal on Cardiac, Vascular and Thoracic Surgery

Indexed/Abstracted in: BIOSIS Previews, Current Contents/Clinical Medicine, EMBASE, PubMed/MEDLINE, Science Citation Index Expanded (SciSearch), Scopus
Impact Factor 1,632




The Journal of Cardiovascular Surgery 2015 February;56(1):89-95

language: English

Twelve-month experience with the GORE® TIGRIS® Vascular Stent in the superficial femoral and popliteal arteries

Piorkowski M. 1, Freitas B. 2, Steiner S. 3, Botsios S. 4, Bausback Y. 3, Scheinert D. 3, Schmidt A. 3

1 Cardioangiological Center Bethanien (CCB), Frankfurt am Main, Germany;
2 Universidade Federal do Vale do Sao Francisco, Petrolina, Brazil;
3 Department for Interventional Angiology, University Hospital Leipzig, Leipzig, Germany;
4 Faculty of Health, Witten/Herdecke University, Witten, Germany


AIM: The aim of this paper was to report the continued mid-term follow-up of the first patients world-wide treated with the GORE® TIGRIS® Vascular Stent, a dual component stent consisting of a nitinol wire frame combined with a fluoropolymer-interconnecting structure.
METHODS: From December 2011 until November 2012, 32 consecutive patients (20 men, mean age 72.8 years) with 40 atherosclerotic femoropopliteal lesions (5% occlusions) underwent angioplasty and implantation of a GORE® TIGRIS® Vascular Stent. The patients were scheduled for follow-up at 3, 6 and 12 months after stent implantation for duplex ultrasound and assessment of Rutherford-Becker class (RBC) and Ankle-Brachial Index (ABI). Here we report the completed 6-month follow-up and, for the first time, a 12-month follow-up.
RESULTS: The median follow-up was 418 days. During the 12-month follow-up 4 patients died. Restenosis or reocclusion of the stent in this time period was observed in 5 lesions (12.5%), resulting in a cumulative primary patency rate of 85.5±6.0%. The ABI increased pre-interventionally from 0.65±0.18 to 0.91±0.18 (P<0.0001) at the 12-month visit. The median RBC improved from 3 to 1 (P<0.0001). No stent thrombosis related to discontinuation of dual antiplatelet therapy 4 weeks after the index procedure was observed.
CONCLUSION: The mid-term follow-up of the dual component GORE® TIGRIS® Vascular Stent showed promising results with high 12-month primary patency rates after femoropopliteal endovascular interventions. These first clinical data are very promising compared to other stent concepts in the superficial femoral and popliteal artery.

top of page

Publication History

Cite this article as

Corresponding author e-mail